Compared with pre-surgical (neoadjuvant) chemotherapy alone, adding perioperative immunotherapy – given before and after surgery – significantly improved event-free survival (EFS) in patients with resectable early-stage non-small cell lung cancer(NSCLC), according to researchers from The University of Texas MD Anderson Cancer Center.
Sanofi, OpenAI, Formation Bio announce AI drug development partnership
French pharmaceutical giant Sanofi will work with the tech powerhouse OpenAI and New York-based startup Formation Bio to develop AI-powered software in drug R&D, the
May 22, 2024